What's Happening?
U.S. Representatives Beth Van Duyne and Greg Landsman have introduced the Beverage Regulatory Parity Act, a bipartisan bill aimed at regulating intoxicating hemp beverages similarly to alcohol. The proposed legislation seeks to establish a federal framework
for the sale of these beverages, including a three-tiered distribution system, product labeling, advertising, and trade-practice rules modeled after alcohol regulations. The bill also proposes setting the minimum age for purchasing or consuming hemp products at 21 and includes product testing requirements. Additionally, a federal excise tax of 8 cents per milligram of intoxicating THC in each beverage is proposed. The legislation comes in response to a looming federal prohibition on the sale of hemp-derived THC products, set to take effect in December.
Why It's Important?
The introduction of the Beverage Regulatory Parity Act is significant as it addresses the growing market for hemp-derived intoxicating beverages, which has been operating in a regulatory gray area. By aligning the regulation of these products with existing alcohol laws, the bill aims to provide clarity and stability for businesses and consumers. This move could prevent the market from going underground, ensuring safety and compliance while allowing businesses to continue operations. The legislation also highlights the need for federal oversight in emerging markets, balancing consumer choice with public safety. The bill's success could set a precedent for how other cannabis-related products are regulated in the future.
What's Next?
If passed, the Beverage Regulatory Parity Act would create a structured regulatory environment for hemp beverages, potentially influencing state-level regulations. States would have the option to impose stricter requirements or ban the products entirely. The bill's progress will be closely watched by industry stakeholders, including businesses and consumer advocacy groups, as it could significantly impact the market landscape. The legislation's advancement through Congress will likely involve discussions on public health implications, economic benefits, and the role of federal versus state regulation in the cannabis industry.
